AI BioDesign accelerator combines AI with nature

The Fred Hutch Cancer Centre and the Allen Institute (University of Washington) have collaborated to create AI BioDesign.

AI BioDesign is an accelerator that will use AI, large-scale experiments and open science to create new biological solutions. The AI BioDesign team will generate open models, datasets, assays and scientific tools to improve human health, address environmental challenges and spur advanced technologies.

“For the first time, the speed of AI is beginning to match the experimental power of synthetic biology,” said Nobel laureate David Baker, lead scientific director of AI BioDesign, director of the UW Medicine Institute for Protein Design, and a Howard Hughes Medical Institute investigator. “That changes the question from ‘what has nature already made?’ to ‘what else is possible, and how can we test it?’ AI BioDesign can help turn that vast unknown into models that can help us solve some of humanity’s hardest problems.”

The aim is to learn and model biological rules for building life. This could help to develop drugs combatting cancer and neurodegeneration, for example.

Supported by Fund for Science and Technology (FFST), a private foundation in the Paul G. Allen philanthropic ecosystem, AI BioDesign brings together multiple perspectives: the Allen Institute’s experience building large-scale, open-science platforms; the University of Washington’s expertise in synthetic biology and genome science, such as the Institute for Protein Design and UW Medicine Brotman Baty Institute for Precision Medicine; and Fred Hutch’s depth in cellular systems, genomics, and translational medicine.

“AI BioDesign combines this approach with AI models to guide which data we generate next, so experiments and models improve together in a continuous cycle of learning and testing,” said Rui Costa, Allen Institute president and CEO. “Ultimately, that can help us design new biological functions with greater precision.”

AI BioDesign will create a continuous learning platform for biological design. AI models will propose new biological designs, scientists will build and test those designs at scale, and the results will feed back into the models such that each round becomes more accurate and informative. Over time, this design-build-measure-learn cycle will help researchers move from trial and error toward more predictable biological engineering.

AI BioDesign joins a fast-moving field. Around the world, teams are building foundation models, virtual-cell systems, lab-in-the-loop platforms, and AI-enabled discovery pipelines. AI BioDesign is designed to complement those efforts by creating an open, experimentally grounded research accelerator that produces reusable resources for the broader scientific community.

Its distinction lies in the combination of multiple modular models built from tractable biological problems; new data generated from designed biological sequences and perturbations; multiplex experiments that test many designs at once; and the open sharing of models, datasets, assays, reagents, and benchmarks.

Share This Article
Editor
Follow:
Saskia Henn is a digital journalist at Scientist Live and editor of International Mining Engineer and International Oil and Gas Engineer. With a background in marine technology and news, she joined Setform in 2024 as a staff writer and enjoys writing across all of the company's magazines. Saskia holds a BA in Communication Science from the University of Amsterdam and an MA in Journalism from the University of London, Goldsmiths.
Leave a Comment

Subscribe to our Newsletter

© 2026 Setform Limited.